AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02324933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl Patient Controlled Analgesia for post-operative pain management
Study NCT04027153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fee based delivery
Description: Testing willingness to pay for services to simplify delivery is innovative as the strategy could increase funds for HIV care making home delivery cost neutral.
Study NCT04027153 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fee based delivery
Description: Testing willingness to pay for services to simplify delivery is innovative as the strategy could increase funds for HIV care making home delivery cost neutral.
Study NCT02843074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally (PO) or by IV
Study NCT02843074 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous stem cell transplantation
Study NCT00450827 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT02933593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol
Description: To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
Study NCT02225639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 70 mg
Description: Oral 70 mg capsule - active
Study NCT02225639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PRC-063 70 mg
Description: Oral 70 mg capsule - active
Study NCT02225639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 85 mg
Description: Oral 85 mg capsule - active
Study NCT02225639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PRC-063 85 mg
Description: Oral 85 mg capsule - active
Study NCT02225639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRC-063 100 mg
Description: Oral 100 mg capsule - active
Study NCT02225639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PRC-063 100 mg
Description: Oral 100 mg capsule - active
Study NCT01908075 — intervention group
Intervention type: DRUG
Intervention: FP/SAL
Study NCT01908075 — intervention group
Intervention type: DRUG
Intervention: BDP/FOR
Study NCT01016951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9164 Turbuhaler®
Description: Dry powder for inhalation via Turbuhaler, MAD. Starting dose in healthy volunteers is 400 µg with up to two dose escalations not exceeding AstraZeneca pre-defined exposure limits.~The COPD patients will receive a dose of 1000 µg.
Study NCT00450827 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00450827 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Study NCT00450827 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 131 monoclonal antibody 3F8
Study NCT00688636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infliximab
Description: 5 mg/kg IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6
Study NCT00688636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6
Study NCT01016951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Turbuhaler®
Description: Dry powder for inhalation via Turbuhaler, MAD
Study NCT04195204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropisetron
Description: Investigators administrated intravenously Tropisetron 5mg before anesthesia and once daily for 7 days after surgery.
Study NCT04195204 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Investigators administrated intravenously saline solution as a placebo
Study NCT03622684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle relaxation according to Jacobson
Study NCT05031611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intuitive Eating Treatment
Description: Participants received a brief web-based intervention for disordered eating which focused on a style of eating behavior called intuitive eating. Please see arm description for more details.
Study NCT02124200 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EGO/CE4, 9mg nicotine
Study NCT02639624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low bicarbonate dialysate First
Study NCT02639624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal bicarbonate dialysate First
Study NCT02639624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal bicarbonate dialysate
Study NCT02639624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low bicarbonate dialysate
Study NCT03978663 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy
Description: Neoadjuvant radiation therapy delivered to a portion of the index tumour for high-risk breast carcinoma for immune priming prior to neoadjuvant radiation
Study NCT03291080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liquid 13-Cis Retinoic Acid
Description: Liquid 13-Cis Retinoic Acid
Study NCT03291080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extracted capsules 13-CRA
Description: Extracted capsules 13-CRA
Study NCT02741960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: 500 mg metformin three times daily
Study NCT02741960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 500 mg placebo three times daily
Study NCT02935062 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Phonological Therapy
Description: Phonological therapy based on generalizing the sounds presented by figures, repetition and naming words.
Study NCT02935062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Software Phonological Therapy- SIFALA
Description: The phonological thearapy of this group will be based on software use with phonological model already developed, using naming and repetition of sounds.
Study NCT02935062 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Therapy
Description: No intervention to improve speech.
Study NCT01734681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-202
Study NCT04313231 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Next Generation Sequencing
Description: Sequencing of patient samples will be performed in the facilities of ZIMCL. Following DNA extraction, the sequencing of granulocytes as well as of lymphocytes (control) will be carried out. IN addition to whole exome sequencing, a panel from SOPHIA GENETICS (which is also available for routine diagnostics) will be applied including the following MDS specific genes: ASXL1, BRAF, CBL, CEBPA, CSF3R, DNMT3A, EZH2, FLT3, HRAS, IDH1, IDH2, KRAS, MPL, NPM1, NRAS, RUNX1, SF3B1, SRSF2, TET2, TP53, U2AF1, WT1, ZRSR. Each patient sample will be bulk sequenced, meaning that relevant mutations are detected down to an allele frequency of 2%.
Study NCT04313231 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tumorimmunological examinations - multiplex assays/quantitative polymerase chain reaction
Description: Inflammasome activation is quantified by analyses of inflammasome-associated cytokine patterns. Multiplex assays for the quantification of the inflammasome-specific cytokines will be done from serum as well as from supernatants the stimulated blood cells. Cytokine quantification is carried out with Luminex FlexMap 3D. Serum cytokine levels will be quantitated in parallel.~Quantification of RNA expression levels of inflammasome-related gene products will be performed by qPCRs from unstimulated and stimulated (=cryotube) blood cells. The necessary RNA extraction will be performed using a RNA extraction kit.
Study NCT04313231 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: flow cytometry
Description: A detailed evaluation of the individual immune status is being conducted by the analysis of two specialized panels: Panel A provides a broad overview over various immune cell populations, while Panel B identifies T-cell sup-populations.
Study NCT04313231 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Metagenomics of stool samples
Description: DNA will be extracted from frozen fecal samples applying a bead-beating method using a GNOME DNA Isolation Kit (MP Biomedicals). DNA quality will be assessed using an Agilent 4200 TapeStation (Agilent Technologies). After final precipitation, DNA samples will be re-suspended in TE buffer and stored at -80 °C for further sequencing analysis. To this end, sequencing libraries will be generated using a Nextera XT DNA Sample Prep Kit (Illumina). Library quality will be confirmed using an Agilent 4200 TapeStation. Whole-genome shotgun sequencing of fecal samples will be carried out on a HiSeq2500 platform (Illumina).
Study NCT04313231 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical/demographic data
Description: Demographic and clinical data include: age, age at initial diagnosis, sex, diagnosis, actual comorbidities, medication at inclusion in study, cytogenetic and molecular profiles and standard laboratory parameters (blood count, differential leukocyte count, biochemistry, iron status, inflammatory markers like CRP, albumin, fibrinogen).
Study NCT04313231 — intervention group
Intervention type: OTHER
Intervention: Elicitation of the HRQoL
Description: Evaluation of HRQOL, of functional activities and of performance status will be done by the patient and/or the physician using validated scores.
Study NCT04541238 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Magnetic resonance imaging
Study NCT02384954 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous infusion 375 mg/m\^2.
Study NCT02384954 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: Intravenous infusion for Phase 1 cohort 1, 2 and 3; subcutaneous injection for Phase 1 cohort 4, 5, 6 and 7. Phase 2 dosing was based off of the MTD determined in Phase 1.
Study NCT04013711 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Thermography
Description: Thermograms will be acquired of both treated and non-treated cancer site for comparison.
Study NCT03288662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT and histopathological classification
Description: Cross-sectional descriptive study on 53 patients with diagnosed of thymoma by CT and had postoperative histopathology results as thymic epithelial tumors. Base on the characteristics in Chest CT scan in each postoperative histopathology results.
Study NCT00566267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin 20 mg/ezetimibe
Description: see protocol
Study NCT01612403 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: zinc sulfate
Description: every participant took two capsules of zinc sulfate per day for three months (each one 220mg)
Study NCT02596815 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Median Nerve Neural Mobilization
Description: Nonsurgical noninvasive Median Nerve neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The maximum level of elbow extension movement degree without the reproduction of symptoms during the application of the Median Nerve Neural mobilization treatment was determined through the baseline use of a Universal Goniometer Device.
Study NCT02596815 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Median Nerve Neural Mobilization
Description: Nonsurgical noninvasive Median Nerve neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The maximum level of elbow extension movement degree without the reproduction of symptoms during the application of the Median Nerve Neural mobilization treatment was determined through the baseline use of a Universal Goniometer Device.
Study NCT02596815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goniometer
Study NCT02596815 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goniometer
Study NCT00672074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipamorelin
Description: IV
Study NCT00672074 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV
Study NCT01474681 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSC835
Study NCT03947918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short sleep
Description: Child will be asked to sleep for less than 8 hours. Study team will help parent design a sleep schedule for that week. Study team will send parent daily text messages or phone call reminders.
Study NCT03947918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Long sleep
Description: Child will be asked to sleep for more than 10 hours. Study team will help parent design a sleep schedule for that week. Study team will send parent text messages or phone call reminders.
Study NCT02933593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydralazine
Description: To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
Study NCT02933593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nifedipine
Description: To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
Study NCT04519489 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAP therapy with telemonitoring
Description: This study intends to investigate effect of PAP therapy on reducing AF recurrence rate in the patients in co-morbidity of OSA. The study will use 2 investigational devices: Philips DreamStation and Philips EncoreAnywhere. Philips DreamStation is used as the PAP therapy device to provide PAP therapy on the study subjects; Philips EncoreAnywhere is used as a telemonitoring service to provide monitoring by physicians that ensure good adherence to PAP. In addition, subjects in the intervention group will also receive AFib standard management and OSA general care.
Study NCT04519489 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: AF standard management and OSA general care
Description: Subjects in the control group will receive AF standard management and OSA general care. The treatment, medical care, and AF management for the subjects will be performed at the study hospitals following the newly updated Chinese AF management guideline 'Current knowledge and management recommendations of atrial fibrillation: 2018'.All subjects including the intervention group and the control group will receive the education materials to understand the disease, risk, and management of OSA. All subjects will also receive the general intervention for OSA, including suggestions for body weight control, smoking cessation, alcohol limiting, lateral position sleep, etc.
Study NCT02274467 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trans-catheter electric stimulation test
Study NCT03201471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide + R-CHOP regimen
Description: Patients will receive 2 courses of Chidamide+ R-CHOP regimen, the way of administration and dosage of the medicine used in the trial is as follows: Rituximab 375mg//m2, ivgtt,d1;CTX 750mg/m2, ivgtt,d2;EPI 70mg/m2, ivgtt,d2;VCR 1.4 mg/m2, ivgtt, d2; Pred 60 mg/m2,PO, d2-6; Chidamide 20mg/d,d1、4、8、11、14、18;one cycle every 21 days;
Study NCT02330081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirasol treatment of whole blood
Description: Subject will be infused with two products at the same time:~1. radio-labeled platelets derived from subject's stored whole blood which has been treated with Mirasol.~2. radio-labeled platelets derived from subject's untreated fresh whole blood.
Study NCT00423800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)
Description: 1. Powder for Solution in Redipen® (pegylated interferon alfa-2b) (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 or 48 weeks~2. 200 mg ribavirin capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 or 48 weeks
Study NCT00423800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)
Description: 1. Powder for Solution in Redipen® (pegylated interferon alfa-2b) (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 or 48 weeks~2. 200 mg ribavirin capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 or 48 weeks
Study NCT01572961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicilic acids (Aspirin)
Description: single oral dose of 1g.
Study NCT00323895 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug-eluting stent and balloon angioplasty
Description: CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand
Study NCT00323895 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drug-eluting stent and balloon angioplasty
Description: CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand
Study NCT00323895 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drug-eluting stent
Description: CYPHER Select ™ Sirolimus-eluting Stent
Study NCT01379521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Study NCT01379521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: everolimus placebo
Study NCT04389983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Medium Chain Triglyceride oil
Description: Bulletproof Braine Octane MCT oil
Study NCT00938041 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tositumomab and Iodine I 131 Tositumomab
Description: Tositumomab and Iodine I 131 Tositumomab
Study NCT01408368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral subtotal thyroidectomy
Description: The intervention consisted of bilateral subtotal thyroidectomy (leaving on both sides of the neck thyroid stumps of approximately 2 g of normal remnant tissue each).
Study NCT01408368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy
Description: The intervention consisted of total extracapsular thyroidectomy.
Study NCT04586101 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trainings application
Description: Participants have to train with the developed trainings application over six weeks. For this, individual training plans are implemented in the application based on orthopedic joint status and training recommendations of a sports scientist.
Study NCT04051229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6-week exercise training program
Description: Participants will walk at 50% Heart Rate Reserve (HRR) 3 to 5 days per week for 6 weeks at the Department of Health and Exercise Science Clinical Research Center under the supervision of study staff.
Study NCT01572961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04269278 — intervention group
Intervention type: DRUG
Intervention: 0 ul of dexmedetomidine
Description: Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0 ul) using dexmedetomidine
Study NCT04269278 — intervention group
Intervention type: DRUG
Intervention: 0.25 ul of dexmedetomidine
Description: Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.25 ul) using dexmedetomidine
Study NCT04269278 — intervention group
Intervention type: DRUG
Intervention: 0.5 ul of dexmedetomidine
Description: Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.5 ul) using dexmedetomidine
Study NCT04269278 — intervention group
Intervention type: DRUG
Intervention: 0.75 ul of dexmedetomidine
Description: Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.75 ul) using dexmedetomidine
Study NCT00310427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY686017
Description: 50 mg administered orally on a daily basis
Study NCT00310427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered on a daily basis
Study NCT01821027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: One 40 mg tablet taken orally (by mouth) on Day 1 and Day 7.
Study NCT01821027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: One 300 mg dose (ie, one 100 mg and one 200 mg over-encapsulated tablet) taken orally (by mouth) on Days 2 through Day 7.
Study NCT00905489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine Immediate Release (IR)
Description: 200 mg Tablet or 50 mg / 5 ml oral suspension
Study NCT00905489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine Extended Release (XR)
Description: 200 mg, 300 mg or 400 mg Tablet formulation